Use of myeloablative Y90-ibritumomab tiuxetan in patients with high-risk CD20+ NHL not eligible for standard ASCT: Five-year results.
L. Devizzi
No relevant relationships to disclose
A. Guidetti
No relevant relationships to disclose
C. Carlo-Stella
No relevant relationships to disclose
C. Tarella
No relevant relationships to disclose
E. Seregni
No relevant relationships to disclose
M. Magni
No relevant relationships to disclose
M. A. Di Nicola
No relevant relationships to disclose
E. Schiavello
No relevant relationships to disclose
P. Matteucci
No relevant relationships to disclose
S. Viviani
No relevant relationships to disclose
E. Bombardieri
No relevant relationships to disclose
A. M. Gianni
No relevant relationships to disclose